Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION: TNT for cT2 Rectal Cancer
NCT05939661Phase 2Recruiting
- Sponsor
- The University of Osaka
- Start
- May 2023
- Primary completion
- Mar 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in rectal cancer, sponsored by The University of Osaka. Primary endpoint: Pathological Complete Response at 6 months. Started May 2023; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05939661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939661.